RCKT · XBRL financial data

Rocket Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RCKT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	0	0	0	0	0	0
Research and development	106	125	166	186	171	142
General and administrative	28	42	59	73	102	87
Total operating expenses	134	167	224	260	273	232
Operating income (loss)	(134)	(167)	(224)	(260)	(273)	(232)
Interest expense	7	3	2	2	2	2
Income tax expense (benefit)	—	—	—	0	0	0
Net income (loss)	(140)	(169)	(222)	(246)	(259)	(223)
Earnings per share, basic USD per share	(2.52)	(2.67)	(3.26)	(2.92)	(2.73)	(2.01)
Earnings per share, diluted USD per share	(2.52)	(2.67)	(3.26)	(2.92)	(2.73)	(2.01)
Weighted average shares, basic millions of shares	55	63	68	84	95	111
Weighted average shares, diluted millions of shares	55	63	68	84	95	111

Fiscal years (RCKT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	297	233	141	56	164	78
Short-term investments	186	156	216	317	209	111
Prepaid and other current assets	5	3	8	5	6	4
Total current assets	487	392	364	378	378	193
Property and equipment, net	19	22	29	39	37	28
Right-of-use asset	1	2	2	4	4	3
Goodwill	31	31	39	39	39	39
Total assets	591	497	552	566	528	330
Total current liabilities	33	22	39	49	41	30
Lease liability, non-current	0	1	1	3	3	3
Total liabilities	87	42	62	74	64	53
Accumulated deficit	(323)	(492)	(714)	(959)	(1,218)	(1,441)
Total stockholders' equity	504	455	490	493	463	277
Total liabilities and equity	591	497	552	566	528	330
Common shares outstanding (cover page) millions of shares	62	65	79	91	107	109

Fiscal years (RCKT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(140)	(169)	(222)	(246)	(259)	(223)
Stock-based compensation	19	29	31	39	44	37
Depreciation and amortization	1	3	4	5	7	9
Net cash from operating activities	(75)	(121)	(178)	(195)	(210)	(190)
Purchases of property and equipment	21	8	8	16	6	0
Net cash from investing activities	(97)	19	(69)	(98)	132	104
Proceeds from issuing common stock	281	11	47	—	—	—
Share repurchases	0	0	—	—	—	—
Net cash from financing activities	283	38	155	208	186	0

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Rocket Pharmaceuticals	225	0	(40)*	109.8M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Perspective Therapeutics	48	not reported	(21)*	114.2M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Natures Sunshine Products	89	117	11*	17.3M	—	Q3 FY26 10-QSep 30, 2026
Tvardi Therapeutics	16	not reported	(9.2)*	13.3M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Silence Therapeutics	72	0	1.5*	141.7M	—	Q2 FY26 10-QJun 30, 2026
SELLAS Life Sciences Group	138	not reported	(7.6)*	201.9M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
Precigen	15	74	12*	358.5M	—	Q3 FY26 10-QSep 30, 2026
Cardiff Oncology	9.2	0.1	(12)*	77.8M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Rezolute	11	not reported	(13)*	96.7M	8.2 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.